论文部分内容阅读
目的观察高血压脑出血患者使用丙氨酰谷氨酰胺后肿瘤坏死因子(TNF-α)和热休克蛋白(Hsp-70)血浆水平的变化。方法将62例高血压脑出血患者按治疗方法随机分为Ala-Gln组(32例)和常规组(30例),Ala-Gln组接受丙氨酰谷氨酰胺治疗,常规组使用常规治疗方法,分别于入院当天及治疗第7天测定TNF-α和Hsp-70血浆水平。结果 Ala-Gln组治疗第7天血浆TNF-α水平由入院当天的(45.13±2.96)pg/ml下降至(30.12±2.14)pg/ml,也明显低于常规组的(40.55±2.51)pg/ml,差异有统计学意义(P<0.01)。Ala-Gln组治疗第7天血浆Hsp-70水平由入院当天的(2.15±0.13)g/L增高至(15.48±1.54)g/L,也明显高于常规组的(5.58±0.51)g/L,差异有统计学意义(P<0.01)。结论对高血压脑出血患者补充丙氨酰谷氨酰胺可使血浆Hsp-70水平升高,TNF-α下降,从而降低炎症反应,增强细胞对缺血缺氧的耐受性,抑制细胞凋亡,提高对高血压脑出血患者的治疗效果。
Objective To observe the plasma levels of tumor necrosis factor (TNF-α) and heat shock protein (Hsp-70) in patients with hypertensive cerebral hemorrhage after using alanylglutamine. Methods 62 patients with hypertensive intracerebral hemorrhage were randomly divided into Ala-Gln group (n = 32) and conventional group (n = 30). Patients in Ala-Gln group received alanyl-glutamine treatment. Conventional treatment The plasma levels of TNF-α and Hsp-70 were measured on the day of admission and on the 7th day of treatment respectively. Results The level of plasma TNF-α in the Ala-Gln group decreased from (45.13 ± 2.96) pg / ml to (30.12 ± 2.14) pg / ml on the day of admission and significantly lower than that of the conventional group (40.55 ± 2.51) pg / ml, the difference was statistically significant (P <0.01). The level of Hsp-70 in the Ala-Gln group increased from (2.15 ± 0.13) g / L on the day of admission to (15.48 ± 1.54) g / L on the seventh day and was significantly higher than that of the conventional group (5.58 ± 0.51) g / L, the difference was statistically significant (P <0.01). Conclusions Alanylglutamine supplementation with hypertensive intracerebral hemorrhage can increase plasma Hsp-70 level and decrease TNF-α, thereby reducing the inflammatory reaction, increasing the tolerance of cells to hypoxia and hypoxia, and inhibiting apoptosis , Improve the treatment of patients with hypertensive intracerebral hemorrhage.